A Closer Look at Global Health Research and Development

By HEOR Staff Writer

December 29, 2023

Global Health Research and Development

Advancing Health Research on a Global Scale

Global Observatory on Health Research and Development (R&D) of the World Health Organisation (WHO) has just debuted its most current results. The report’s depiction of severe inequalities in the allocation of resources, money, and capacity for global health research was not unexpected. There is obviously a divide between nations with high incomes and those with low or medium incomes. The publication of this finding in the journal Health Research Policy and Systems highlights the importance of thoroughly reevaluating strategies and financial decisions for health research and development.

The Critical Need to Resolve Past Inequities

The recent COVID-19 pandemic and other outbreaks such as mpox underscore the urgent need for a fairer allocation of health research funds. Despite numerous discussions and proposals, the disparity in resource distribution between wealthy and poor nations remains largely unaddressed. This issue is critical not only for disaster preparedness but also for the global goal of improving population health equitably.

Important Results from the Worldwide Health Research and Development Project

The report highlighted four major issues. In 2020, low-income nations received just 0.2% of all grant funding, highlighting the huge disparity in this area. As a second point, the disparity in research capacity is exacerbated by the fact that high-income nations have around 56 times more health researchers per million resident than low-income countries. Third, there is a dearth of research training possibilities in low-income nations due to the low density of higher education institutions relative to the population. Finally, the suggested goals for health R&D spending as a proportion of GDP were unmet by a number of nations.

The Need to Take Action

Consistent gaps in health research capacity and financing are highlighted by the results. There has been no improvement in decades of acknowledgment. The paper recommends a systematic approach to data collection and prioritises research. It promotes frequent data exchange and advocates for global collaboration in solving these problems.

The Global Observatory on Health Research and Development remains a vital tool today. It monitors and analyses data on health research and development. It highlights both the opportunities and challenges in this crucial sector. If the international community collaborates to bridge the knowledge gap, we can improve health outcomes for all. 

Reference url

Recent Posts

cemdisiran gMG treatment
Breakthrough in cemdisiran gMG treatment Advances Regulatory Landscape

By João L. Carapinha

June 25, 2026

Cemdisiran gMG treatment has cleared a critical hurdle after the FDA and EMA accepted Regeneron’s regulatory submissions for review in anti-AChR antibody-positive generalized myasthenia gravis (gMG). The investigational siRNA therapy targeting complement protein C5 could become the first subcutan...
Trodelvy ADC approval
Advancements in Breast Cancer Treatment Following Trodelvy ADC Approval

By João L. Carapinha

June 25, 2026

The Trodelvy ADC approval by the European Commission delivers the first antibody-drug conjugate approved for first-line use in adults with unresectable or metastatic triple-negative breast cancer who are ineligible for PD-1 or PD-L1 inhibitors. This
Cemiplimab Cervical Cancer Access
Cemiplimab Cervical Cancer Access Navigating Treatment and Value

By João L. Carapinha

June 24, 2026

Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...